Using telemedicine to facilitate thrombolytic therapy for patients with acute stroke.
BACKGROUND
Recent stroke-care requirements state that all stroke patients should be screened for intravenous recombinant tissue plasminogen activator (rt-PA) and treated, if the appropriate inclusion and exclusion criteria are met. Two community hospitals 90-130 miles east of Houston deployed telemedicine (videoteleconferencing) to provide acute stroke consultative services. DEVELOPING A TELEMEDICINE CAPACITY: According to the Brain Attack Coalition's recommendations, neurosurgical services need to be accessible within two hours. Given their incomplete neurology coverage, the remote-site hospitals identified telemedicine as the best option, with the University of Texas Health Science Center at Houston stroke team as the provider of expertise.


RESULTS
In the 13 months preceding the telemedicine project (January 2003-March 2004), 2 (.8%) of 327 patients received rt-PA, compared with 14 (4.3%) of 328 patients during the telemedicine project (April 2004-May 2005), p < .001). Seven patients had > or = 4 points improvement in a stroke scale at 24 hours posttreatment. Three patients worsened during the 24-hour assessment. No intracerebral hemorrhages occurred. Door-to-needle median time was 85 minutes (range, 27-165 minutes).


CONCLUSIONS
Telemedicine facilitated thrombolytic therapy for acute stroke patients and is intended not to replace care provided by remote-site providers but rather to address a time- and spatially related emergency need.
Choi
John Y
JY
Department of Neurology, University of Texas Health Science Center, Houston, USA. John.Y.Choi@uth.tmc.edu
Porche
Nichole A
NA
Albright
Karen C
KC
Khaja
Aslam M
AM
Ho
Victor S
VS
Grotta
James C
JC
D000208:Acute Disease; D006764:Hospitals, Community; D006801:Humans; D019982:Organizational Case Studies; D012017:Referral and Consultation; D020521:Stroke / Q000188:drug therapy*; D017216:Telemedicine / Q000379:methods*; D013781:Texas; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator
D010959:Tissue Plasminogen Activator